Trileptal and Nabumetone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trileptal (oxcarbazepine) and Nabumetone (nabumetone). Common drug interactions include dyspnoea among females and dependence among males.

The phase IV clinical study analyzes what interactions people have when they take Trileptal and Nabumetone. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Trileptal?

Trileptal has active ingredients of oxcarbazepine. It is often used in bipolar disorder. eHealthMe is studying from 23,558 Trileptal users. Check the latest studies of Trileptal.

What is Nabumetone?

Nabumetone has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 9,554 Nabumetone users. Check the latest studies of Nabumetone.



On Jul, 09, 2026

30 people who take Trileptal and Nabumetone together, and have interactions are studied.

Trileptal and Nabumetone drug interactions.

What are the common drug interactions of Trileptal and Nabumetone, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Diarrhoea
  3. Cough
  4. Fatigue (feeling of tiredness)
  5. Hyperhidrosis (abnormally increased sweating)
  6. Nausea (feeling of having an urge to vomit)
  7. Arthralgia (joint pain)
  8. Back pain
  9. Balance disorder
  10. Blood pressure increased

male:

  1. Dependence
  2. Headache (pain in head)
  3. Haematological malignancy (cancer that affect blood, bone marrow, and lymph nodes)
  4. Mood swings (an extreme or rapid change in mood)
  5. Nausea (feeling of having an urge to vomit)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Suicidal ideation
  8. Vomiting
  9. Hypertension (high blood pressure)
  10. Overdose

What are the common drug interactions of Trileptal and Nabumetone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Anxiety
  2. Cholecystitis chronic (long lasting infection of gallbladder)
  3. Emotional distress
  4. Gallbladder injury

20-29:

  1. Dependence
  2. Headache (pain in head)
  3. Hypertension (high blood pressure)
  4. Overdose
  5. Decreased appetite
  6. Diarrhoea
  7. Mood swings (an extreme or rapid change in mood)
  8. Nausea (feeling of having an urge to vomit)
  9. Suicidal ideation
  10. Vomiting

30-39:

  1. Death
  2. Hypersensitivity
  3. Pruritus (severe itching of the skin)
  4. Suicidal ideation
  5. Urticaria (rash of round, red welts on the skin that itch intensely)

40-49:

  1. Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
  2. Blood cholesterol increased
  3. Blood triglycerides increased
  4. Dysphagia (a condition in which swallowing is difficult or painful)
  5. Dyspnoea (difficult or laboured respiration)
  6. Injection site pain
  7. Injection site rash
  8. Insomnia (sleeplessness)
  9. Kyphosis (a condition of over-curvature of the thoracic vertebrae (upper back))
  10. Lordosis (outward curve of the back bone)

50-59:

  1. Hyperhidrosis (abnormally increased sweating)
  2. Dizziness
  3. Dyspnoea (difficult or laboured respiration)
  4. Fall
  5. Fatigue (feeling of tiredness)
  6. Feeling cold
  7. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  8. Headache (pain in head)
  9. Loss of consciousness
  10. Muscular weakness (muscle weakness)

60+:

  1. Diarrhoea

What are the existing conditions these people have? *

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 20.00%
  2. Depression: 6 people, 20.00%
  3. Pain: 4 people, 13.33%
  4. Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 3 people, 10.00%
  5. Stress And Anxiety: 3 people, 10.00%
  6. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 3 people, 10.00%
  7. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 3 people, 10.00%
  8. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 3 people, 10.00%
  9. Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 6.67%
  10. Premenstrual Syndrome: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Trileptal and Nabumetone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Trileptal and Nabumetone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trileptal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nabumetone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Trileptal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nabumetone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on oxcarbazepine and nabumetone (the active ingredients of Trileptal and Nabumetone, respectively), and Trileptal and Nabumetone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: